Table 4.
Incidence of vertebral fracture over 3 years of treatment with strontium ranelate (SR) compared with placebo, according to tertiles of pre-treatment b-ALP and sCTX level
| Tertile 1 | Tertile 2 | Tertile 3 | ||||
|---|---|---|---|---|---|---|
| SR | Placebo | SR | Placebo | SR | Placebo | |
| By b-ALP level | ||||||
| Eventsa | 114 | 155 | 107 | 175 | 115 | 203 |
| Incidence (%) | 14.9 | 21.1 | 14.3 | 23.7 | 16.4 | 26.5 |
| Relative risk [95% CI] | 0.69 [0.54; 0.88] | 0.58 [0.46; 0.74] | 0.58 [0.46; 0.73] | |||
| p value | 0.003 | <0.001 | <0.001 | |||
| Relative risk reduction (%) | 31 | 42 | 42 | |||
| Absolute risk reduction (%) | 6.2 | 9.4 | 10.2 | |||
| NNT | 17 | 11 | 10 | |||
| By sCTX level | ||||||
| Eventsa | 105 | 153 | 122 | 181 | 103 | 195 |
| Incidence (%) | 13.8 | 21.2 | 16.9 | 24.1 | 14.7 | 26.3 |
| Relative risk [95% CI] | 0.63 [0.49; 0.81] | 0.68 [0.54; 0.85] | 0.53 [0.42; 0.67] | |||
| p value | <0.001 | <0.001 | <0.001 | |||
| Relative risk reduction (%) | 37 | 32 | 47 | |||
| Absolute risk reduction (%) | 7.4 | 7.2 | 11.6 | |||
| NNT | 14 | 14 | 9 | |||
CI confidence interval, NNT number needed to treat
aTotal number of patients having at least one new vertebral fracture during the 3-year period